USA — Global IT solution provider Accenture has bolstered its capabilities in the life sciences sector with the acquisition of Bionest, a management consultancy with nearly 50 staff in Paris and New York.
Bionest was founded in 2003 in Paris with an exclusive focus on working with businesses in the life sciences market, and in 2012 merged with New York-based Scisive Consulting.
The company has expertise in biomarker testing, helping bring medical innovations to patients, helping bring cell and gene therapies to market, and improving the use of digital technology in life sciences value chains and product lifecycles.
Bionest’s focus on go-to-market strategy in life science’s most exciting and challenging areas will broaden and deepen Accenture’s capabilities.
Scientific and technological advancements are creating breakthroughs for patient health, resulting in more complex and personalized therapies.
This New Science, a dynamic combination of the best in science and health technology, is expected to drive 81 percent of biopharma revenue growth.
However, biopharma companies must also juggle increasingly complex commercialization challenges, patient access issues, and a changing regulatory and economic environment to achieve that growth.
As a result, biopharma companies must constantly assess their go-to-market strategy to maintain a competitive edge.
Welcoming the 46-strong team from Bionest to the firm, Accenture senior managing director Brad Michel said: “The addition of their highly skilled team of experts expands our capabilities and will support our clients in bringing therapeutics to patients faster and more efficiently.”
As part of the integration, Bionest will join Accenture Strategy, the group’s consulting wing, as well as the Life Sciences practice, across offices in France and the United States.
Bionest’s clients include both major established and emerging pharmaceutical and biotechnology brands, chiefly in North America and Europe.
The acquisition is the latest in a long line of consulting acquisitions in the life sciences sector.
Accenture, which is ranked first on the CRN 2022 Solution Provider 500 list, is still one of the most acquisitive companies in the IT industry.
Bionest is the company’s third acquisition since January 1, following the purchases of European regulatory-focused consultant SKS Group and Oracle-focused digital supply chain consultant Inspirage in January.
In 2022, Bain & Company acquired a minority stake in Trinity Life Sciences, Sia Partners acquired Latham BioPharm Group, and BDO acquired life sciences specialist AdaptaLogix among others.
Oliver Wyman joined Huron’s life sciences strategy practice in the United States in 2021.